The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
this meerkat is really pig****e crazy. following on from recent contract news they launch ‘ first of many’ new winterlight diagnostic products which is expected to yield £15 million in revenue within 5 years, having already wontheir first contract with it. definitely be loading up more when funds allow.
Interesting that this is the first contract following the acquisition of Winterlight labs and using their technology combined with CANTAB.
I also note an increased order book to £19.9M.
Interesting Company and appears the bottom may have been reached, with plenty of upside.
Looking at their investor base & share issue I imagine this could move fairly quickly.
Considering taking a reasonable position here.
Promising contract news. More like this please
Brett Gordon ( 4th largest holder) upped stake .5%
As one would expect a very robust and positive fighting talk In the webinar. Key pointe being no need for further funding. Second half well on track to deliver. Glossed over the funding issue bit. I think it’s fair to assume that contract delays caught them out a bit and probably hoped that they could get away with completing acquisitions without further funding. So we had better hope this really is it. Talked about competition, sounds like inferior cheaper products provided for by less accurate solutions . Sounds like they are pretty unique top end of accuracy in the Clinical trials market, with 10 of top 20 pharmaceuticals as clients. 60/40 split ints/Pis shareholders . ‘Hindsight is a beautiful thing.’ Obviously they could have done a placing at time of acquisition but actually on reflection I think the loan note was the better option to dilutions probably works out cheaper if everything goes to plan ( ha ha) . Market over reaction? That’s up to them now to prove it.
I’m sure all will be revealed tomorrow in the webinar - seems a total overreaction, albeit in favour of our new warrant holder. I’m sure out biggest shareholder was consulted beforehand and therefore I’m pretty cool.
I was wondering that myself. Interesting to release loan note and interim on the same day. Clearly the market was not expecting this. Don’t know if it’s the results or the loan note which had the biggest effect but that’s a fair percentage right there. May be they approached their broker asked the fund managers and they all said loan note. small placing would have had about the same effect on share price but would be 4 million richer less expenses which are always ridiculous. Let’s hope the contracts roll in, obviously there has been a delay so if they are as good as their word ‘should see an upturn in revenue and profitability by year end.’
This loan seems crazy to me as after three years they will have to pay back nearly four million
at 11.5%. Why not a special call on shareholders?
The extraordinary thing is they are in a far better place than when the share price was over £1.20 last year!
Yep agreed. Plenty bubbling around in the the pharma sector. Increase in working capital seems prudent imo.
Maybe not stunning but satisfactory under the circumstances. In the patience box!
Nice bit share price manipulation here and finally the sp goes up after the last close before results. I did manage to prize 3 top ups last week, but it was hard work. Couldnt get a price for ages and finally got in three trades at 92.88. Hope it works out with some stunning results tomorrow. Cant see any other reason for this cloak and dagger market maker.
Real struggle to get any shares today. Had to put in an order and managed to get a couple of small trades online. Why is it they hold the price back. If they stuck to a more realistic price they might get some sellers. Hardly rocket science. They were quite prepared to buy all my shares at 91p though ha bloody ha
They have been busy. Their very good website is more up to date than news on lse. There was an RNS on 6th September about small increase in holding by Cannacord to over 10 %. Look forward to interims on 26th September
Surprised to see so many sells, perhaps they are not sells. Good interview on Vox markets with Vladem Alexandre of Sp Angel. He reckons the use of Ai will
help broaden the market for Cog beyond oncology as well, opening up diagnostics on pretty well any treatment of many diseases.
And again, more than just another contract. I never considered the oncology side if things.
And just landed another 2 million contract
Just listened to the webinar. Impressed/happy shareholder here.
Exactly as the January update stated 25 percent increase in revenue significantly ahead of expectations and the sp has dropped 30 percent since . Numpty fund manager can’t read?
Solid results, looks well placed for the future
Results, briefing and webinar may 3rd.
Time for the Sunday Times to do a follow-up. LTH myself, so not too fussed with the share price in the short term, although the recent weakness has been a nice opportunity to increase my position. A unique UK company.
Good point Spacerat. Unfortunately still not on most people’s radar hence some rather erratic movements with a general lack of buyers. Hopefully the seller(s) have mostly gone. Really fantastic prospects but may require patience to build strong revenue stream. Certainly seem to have done the groundwork
Sounds better than just another £2m contract. New customer and new field (rare diseases).
Not quite the RNS I was expecting, but very welcome none the less. Results later maybe?